[Details]
Editor’s Note: At Road to Ruin Summit we’re always looking out for special opportunities we believe you, as a valued subscriber, will want to see. Below you’ll find one from our partners at Behind the Markets. Please note that their opinions may differ from ours at Paradigm Press. BREAKING: Tiny Biotech successfully treats blindness Dear Fellow Investor, Can you imagine not seeing your grandchild's face again? Can you imagine having to be led around by your wife when you go out to dinner past 6pm? Can you imagine being confined to your house because you can't drive anymore? For over 7 million people in the U.S. alone, this is their reality. Uncorrectable vision loss is a sad part of life for many people. But I have some amazing news for you - There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. Sound too good to be true? The Nobel Prize Committee is calling it "The Holy Grail of Medicine" The Wall Street Journal reports the company is "transforming medicine." 60 Minutes reports the company is "revolutionizing the search for new drugs." This company has already shown success in human trials... And the potential of this new technology is greater than you can ever imagine. Our research shows that anyone who gets in today could see a 46,751% return. Get the Details Here >>> All the best, Simmy Adelman Editor, Behind the Markets | |
© 2023 Paradigm Press, LLC. 808 Saint Paul Street, Baltimore MD 21202. By submitting your email address, you consent to Paradigm Press, LLC. delivering daily email issues and advertisements. To end your Road to Ruin Summit e-mail subscription and associated external offers sent from Road to Ruin Summit, feel free to click here. Please note: the mailbox associated with this email address is not monitored, so do not reply to this message. We welcome comments or suggestions at feedback@paradigmpressgroup.com. This address is for feedback only. For questions about your account or to speak with customer service, contact us here or call (844)-731-0984. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Road to Ruin Summit is committed to protecting and respecting your privacy. We do not rent or share your email address. Please read our Privacy Statement. If you are having trouble receiving your Road to Ruin Summit subscription, you can ensure its arrival in your mailbox by whitelisting Road to Ruin Summit. |
| |